Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics.
about
CYP2C19 polymorphism influences Helicobacter pylori eradicationIs short-term therapy really sufficient to eradicate Helicobacter pylori infection?High-dose extended-release lansoprazole (dexlansoprazole) and amoxicillin dual therapy for Helicobacter pylori infectionsCharacteristics of non-erosive gastroesophageal reflux disease refractory to proton pump inhibitor therapyVirulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy.Influence of inflammatory cytokine polymorphisms on eradication rates of Helicobacter pylori.Effect of bacterial and host factors on Helicobacter pylori eradication therapyAssociation of helicobacter pylori dupA with the failure of primary eradicationChanges in the Functional Potential of the Gut Microbiome Following Probiotic Supplementation during Helicobacter Pylori Treatment.Preventive medical services not covered by public health insurance at Daiko Medical Center in Japan, 2004-2011.Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pyloriTailored Therapy Versus Empiric Chosen Treatment for Helicobacter pylori Eradication: A Meta-AnalysisNew trends in pharmacogenomic strategies against resistance development in microbial infections.CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection.High-dose versus standard-dose PPI in triple therapy for Helicobacter pylori eradication.Helicobacter pylori eradication: are we really all equal? A controlled study in native and immigrant population.
P2860
Q27005916-4078CEEE-8F1D-4884-A5D0-0A3B253FFE7BQ33678118-EE7005C6-2669-4C27-9B0D-325FF4CF3205Q33953262-642C0A8A-1185-4349-9274-C08DA89311B2Q34831226-F5DB5BA3-17FD-41E3-BA81-F177DC5F05D7Q35056670-A1DE076D-ED06-4E05-8997-2C566C37592BQ35082607-99807AE2-F85D-4469-ADD4-1879EF2B3B62Q35738262-8EFD397A-BBB0-46B4-8B81-AA00472A4BD5Q35812798-11ABAE5C-55E4-4EFA-B0DE-96D3CA874EEBQ35962892-D6F730D8-802A-4D55-803A-7A9F634637B9Q36797183-EEF7EEDD-5F83-4235-BB4F-7023C445EDD3Q37201668-C0C546B4-76EC-4B90-9CA1-8C06E28B8D90Q37206124-3CF12515-9A01-4F85-9250-CA8F1A00935BQ37329167-F89BEE79-B308-4F1C-9B23-7C68609249E0Q37646785-B901AB76-206C-4935-B460-9D7E561DF21AQ39618441-85924E7B-80B9-4F96-9A8D-9D433C19AF51Q43896137-FEDD24CB-EE42-4B32-8049-EF07211445B4
P2860
Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Treatment strategy to eradicat ...... n and alternative antibiotics.
@en
type
label
Treatment strategy to eradicat ...... n and alternative antibiotics.
@en
prefLabel
Treatment strategy to eradicat ...... n and alternative antibiotics.
@en
P2093
P2860
P921
P1476
Treatment strategy to eradicat ...... n and alternative antibiotics.
@en
P2093
Akira Hishida
Chise Kodaira
Hiroshi Watanabe
Kyoichi Ohashi
Masafumi Nishino
Mihoko Yamade
Mitsushige Sugimoto
Mutsuhiro Ikuma
Naohito Shirai
Takahisa Furuta
P2860
P304
P356
10.1517/14656566.8.16.2701
P407
P577
2007-11-01T00:00:00Z